open access
Vol 25, No 4 (2018)
COMMENTARY
Submitted: 2018-08-16
Accepted: 2018-08-16
Published online: 2018-09-12
Get Citation
Providing practical answers to practical questions for NOAC therapy
1
Affiliations- Department of Cardiology, Division of Electrophysiology and Pacing, University Heart Center Zurich, Switzerland
open access
Vol 25, No 4 (2018)
COMMENTARY
Submitted: 2018-08-16
Accepted: 2018-08-16
Published online: 2018-09-12
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Providing practical answers to practical questions for NOAC therapy
Journal
Issue
Pages
441-442
Published online
2018-09-12
Page views
3017
Article views/downloads
1277
DOI
10.5603/CJ.2018.0081
Pubmed
Bibliographic record
Cardiol J 2018;25(4):441-442.
Authors
Jan Steffel
References (11)- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
- Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992.
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–2104.
- Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15(5): 625–651.
- Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467–1507.
- Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330–1393.
- Tomaszuk-Kazberuk A, Kołtowski Ł, Balsam P, et al. Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation — messages from 2018 EHRA. Cardiol J. 2018; 25(4): 423–438.
- Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017; 377(5): 431–441.
- Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015; 169(4): 472–8.e5.
- Cannon CP, Bhatt DL, Oldgren J, et al. RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377(16): 1513–1524.
